6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Published on
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For
the
month of October, 2006
Commission
File Number ________________
Novogen
Limited
(Translation
of registrant’s name into English)
140
Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F
x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes o No
o
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Novogen
Limited
(Registrant)
/s/
Ron Erratt
Ronald
Lea Erratt
Company
Secretary
Date
23 October, 2006
NOVOGEN
LICENCES THE U.S. RIGHTS TO PROMENSIL® AND TRINOVIN® BRANDS
NATROL
CHATSWORTH,
Calif. & STAMFORD, Conn., October 23, 2006
-
Natrol, Inc. (Nasdaq: NTOL), a premier manufacturer and distributor of
nationally branded nutritional products, today announced it has licensed the
U.S. rights to the Promensil® and Trinovin® brands from Novogen Limited (Nasdaq:
NVGN), an Australian-based biotechnology company.
The
Promensil and Trinovin brands are dietary supplements based on red clover
isoflavones that are designed to meet specific health needs of aging adults.
Wayne
M.
Bos, President and CEO of Natrol, stated, “We are excited about our acquisition
of the U.S. rights to Promensil and Trinovin. This acquisition expands Natrol’s
product reach and capabilities with extensive science that will leverage our
promise to provide premium benefits to our customers with quality and
reliability.” He added, “We will capitalize on our strengths in operations,
marketing, sales and distribution to build upon the market presence already
established for these brands.”
Christopher
Naughton, CEO of Novogen, said, "Novogen is extremely pleased to have secured
Natrol as its exclusive licensee for Promensil and Trinovin in the U.S. Natrol
brings marketing expertise and the product critical mass that will enable the
premium brands Promensil and Trinovin to be elevated to their potential in
the
U.S. marketplace."
He
added,
“We believe by out-licensing our dietary supplement lines in the U.S., Novogen
can focus more resources on bringing its biopharma product offerings into the
marketplace.”
Promensil
is a dietary supplement, clinically shown to relieve menopausal symptoms,
including hot flashes and night sweats, and maintain bone and heart health.
Promensil currently is distributed through mass and super center, chain drug
and
grocery stores, the health food channel, and direct sale over the Internet.
Promensil is sold globally in 12 countries, including the U.S.
Trinovin,
which was first sold in the U.S. in 1999, helps maintain prostate and urinary
health. Trinovin currently is distributed through the health food channel and
direct sale over the Internet.
About
Natrol
Founded
in 1980, Natrol, Inc. (Nasdaq: NTOL) is a diversified nutrition company that
manufactures and distributes premium branded nutritional supplements, herbal
teas and sports nutrition products under the Natrol®, Laci Le Beau® and Prolab®
brands, respectively. Natrol markets approximately 50 product categories with
more than 500 stock-keeping units (SKU’s) designed to meet a wide range of
consumer needs. The products are available at thousands of food, drug, mass
market and independent health food stores, catalogs and Internet sites, gyms
and
specialty stores nationally and in select foreign countries. For more
information, visit www.natrol.com.
About
Novogen
Novogen
Limited (Nasdaq: NVGN) is an Australian biotechnology company which has patented
isoflavone technology for the treatment and prevention of degenerative diseases
and disorders. Over the past ten years, Novogen has conducted the largest and
most comprehensive isoflavone clinical testing programs in the world.
Novogen
is involved in drug discovery and product development for disorders that are
commonly associated with aging and coordinates an international clinical
research and development program with external collaborators, hospitals and
universities. For more information, visit www.novogen.com.
The
statements made in this press release which are not historical facts including
statements regarding expectations for future growth of revenue and profits
and
trends concerning net sales, are forward looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the
Securities Exchange Act of 1934, as amended.
You
should be aware that either company’s actual results could differ materially
from those contained in the forward-looking statements, which are based on
either company’s current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, adverse
trends in the dietary supplements industry; intense competition; adverse effects
of unfavorable publicity regarding particular products or either company’s
industry generally; the
risks resulting from either company’s dependence upon, collaboration or
contractual arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any products;
either
company’s dependence on the introduction of successful new
products;
either company’s ability to protect its patents or proprietary rights and obtain
necessary rights to third party patents and intellectual property to operate
its
business; either company’s ability to operate its business without infringing
the patents and proprietary rights of others; general economic
conditions;
either company’s ability to gain market share and shelf space in each of its
distribution channels; either company’s experiencing high rates of product
returns; adverse government regulation; as well as those factors set forth
under
the heading “Risk Factors” in Natrol’s Annual Report on Form 10-K for the year
ended December 31, 2005 and in either company’s other filings with Securities
and Exchange Commission.
|
Investor
Contacts
Natrol
Teri
Lim
Natrol,
Inc.
818-739-6000
Ext. 583
Email:
tlim@natrol.com
|
Novogen
USA:
David
Sheon, for Novogen
202-518-6321
Australia:
Christopher
Naughton
+612
9878 0088
|